MaxCyte and NIH Office Partner to Develop Cell Therapy for Sickle Cell Disease
MaxCyte, a company specialized in cell-based medicines, announced it has entered in a research agreement with the National Heart, Lung and Blood Institute (NHLBI) to develop potential therapies for sickle cell disease (SCD). Researchers will use MaxCyte’s gene-correction platform, Flow Electroporation Technology, in their work. The platform is…